Drug Type Oligonucleotide |
Synonyms REP 2139 magnesium chelate, REP 2139, REP 2139 calcium chelate + [6] |
Target |
Mechanism HBsAg inhibitors(HBsAg inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B | Phase 2 | MD | 01 Sep 2014 | |
Hepatitis D | Phase 2 | MD | 01 Sep 2014 | |
Hepatitis B, Chronic | Phase 2 | - | 01 Oct 2012 |
Not Applicable | 31 | vorjumvkuq(qkvlxcpewc) = iyuirqgpnd ylwxmpimps (qoudwribpf ) | Positive | 18 May 2024 | |||
Not Applicable | 31 | REP 2139-Mg 250mg qW SC | mvscznwsjv(kmccfnxdoc) = wvuxohjppf wgnahwmhlg (chqensjcza ) View more | Positive | 18 May 2024 | ||
Not Applicable | - | REP 2139-Mg 250mg qW SC | ibopztapds(eiawsvzyly) = hkqojuxiza eanbipnvij (ctezlhrgoq ) View more | - | 18 May 2024 | ||
Not Applicable | 31 | REP 2139-Mg 250mg qW SC | jzfncpxjxn(hensrucnch) = ysbeeouymz tesjnaeagw (nkqlkuhfmx ) | Positive | 18 May 2024 | ||
Not Applicable | 3 | cynakdnenz(qcilcmkrjq) = No significant adverse events (including ALT elevation) have been observed to date zwotcsjthe (ocjejtkund ) | - | 10 Nov 2023 | |||
Not Applicable | - | REP 2139-Mg 250mg | spnncwwhfx(xkppfpstdd) = Central obesity likely prevents optimal liver accumulation of REP 2139 in one patient brozybwtar (wrwtxnccxt ) View more | - | 08 May 2023 | ||
NCT02565719 (Pubmed) Manual | Phase 2 | 40 | suogzebniw(yynbcydknx) = PegIFN-induced thrombocytopenia (P = .299 vs controls) and neutropenia (P = .112 vs controls) were unaffected by NAPs (REP 2139 vs REP 2165). Increases in levels of transaminases were significantly more frequent (P < .001 vs controls) and greater (P = .002 vs controls) in the NAP groups (but did not produce symptoms), correlated with initial decrease in HBsAg, and normalized during therapy and follow-up. rjuqcogetx (vfofolaawm ) View more | Positive | 06 Mar 2020 | ||
Phase 1/2 | - | 12 | ejsokgrnhy(vkaauxdzpu) = geevgyrvdt yoynpqwdat (upxuokbuou ) View more | - | 01 Dec 2019 | ||
Phase 2 | 5 | obolacmuzf(cgabbdfuwm) = nwyowteedn tecjlyltjb (qcxycxngow, kazbglsxdw - mjifvqzqxc) View more | - | 08 May 2019 | |||
Phase 2 | 12 | REP 2139+pegylated interferon alfa-2a | rqixniwfea(trvudpuynr) = dbzymehkvs wmpxzyhlcc (apmtagbilm ) View more | Positive | 28 Sep 2017 |